Development of an Optimal Antibiotic Regime for Long-term Therapy in Stable Chronic Obstructive Pulmonary Disease (COPD)

• ClinicalTrials.gov Identifier: NCT01398072
• Recruitment Status: Unknown
• First Posted: July 20, 2011
• Last Update Posted: June 1, 2012
• Sponsor: University College, London
• Collaborators: Royal Free Hampstead NHS Trust; University of Cambridge; National Institute for Health Research, United Kingdom
• Information provided by: University College, London

Study Description

Brief Summary:

Chronic Obstructive Pulmonary Disease (COPD) is the cause of considerable deaths, and exacerbations (flare up of symptoms) are a major cause of hospital admission in the UK. Bacterial infections play an important role in the development of COPD, however, there is little information available about the use of long term antibiotics in the treatment of this disease. Therefore the purpose of this study is to identify the best antibiotic regime for treating patients with COPD who have persistent bacterial infection in their lung. We will test a variety of approaches including both older and newer regimes prescribed either on a daily basis at a lower dose or in "pulsed" courses (for example, every other day or five days every month). The three antibiotics tested in this study are: moxifloxacin, azithromycin and doxycycline. This is a 13 weeks study conducted at the Royal Free Hospital, London. It is expected that approximately 200 patients will be selected for this study. The information we get from this study may help us to treat future patients with COPD better.

Condition or disease	Intervention/treatment	Phase
Chronic Obstructive Pulmonary Disease (COPD).	Drug: Moxifloxacin; Drug: Azithromycin; Drug: Doxycycline; Drug: Placebo	Phase 3

Detailed Description:

This is a 14 week study in which 200 patients with COPD will be selected for this study from GP practices up to a 15 mile radius from the Royal Free Hospital to participate in this study. The 3 antibiotic regimes (plus a placebo group) will be used in this study are:

Moxifloxacin: an oral dose of 400 mg once daily for 5 consecutive days every 4 weeks.

Azithromycin: an oral dose of 250 mg once daily three times a week (every other day).

Doxycycline: an oral dose of 100 mg once daily.

Placebo will be given as one table once daily.

Study recruitment and enrollment will take place through the Primary Care Research Network (PCRN). Potentially eligible participants aged ≥ 45 will be identified from GP practices up to a 15 mile radius from the RFH. Potential eligible patients will be contacted by letter with an accompanying patient information sheet (PIS) describing the study in detail and inviting the patient to attend a hospital visit and enroll. If patients have not responded to the invitation letter, this will be followed by a reminder letter approximately 2 weeks later. Non responders to the reminder letter will be followed up by a final telephone call. Patients expressing an interest in participation will be offered a screening appointment at the Royal Free Hospital. Patients will be asked to visit the hospital 3 times and will be contacted twice by telephone during the course of the study.

At the Screening Visit (V1), the following will take place:

• The study will be discussed again with the patient during this visit and if he/she agree to participate, they will be asked to sign the consent form.
• A medical history of the patient will be taken. This will include smoking history, antibiotic Hypersensitivity, as well as patient concomitant medication.
• A full physical examination will be performed and height and weight of patients will be recorded.
• A lung function test (spirometry assessment) will be performed.
• A blood sample will be collected in order to perform routine haematology/blood chemistry and liver function.
• A sputum sample will be taken and analysed to determine number of bacteria in the lung and to screen for Tuberculosis.
• A urine pregnancy test will be carried out on females of childbearing potential.
• Patients will be asked to complete two sets of questionnaires; "St. George's respiratory questionnaire" (SGRQ) which includes simple questions about the patients COPD condition and how it affects their life; the second an EQ5D questionnaire which includes simple questions relating to the general quality of their life.
• Patients will be given daily diary cards and asked to record their symptoms.
• An ECG will be performed on all patients.

If patients are eligible for the trial, they will be randomised to one of the following groups:

Moxifloxacin: an oral dose of 400 mg once daily for 5 consecutive days every 4 weeks for a total duration of 13 weeks.

Azithromycin: an oral dose of 250 mg once daily three times a week (every other day) for a total duration of 13 weeks.

Doxycycline: an oral dose of 100 mg once daily, for a total duration of 13 weeks Placebo: an oral daily dose of one capsule, for a total duration of 13 weeks.

This is a single-blind trial. Patients will be blinded to treatment; the investigator will be unblinded. Microbiologists will also be blind to treatment allocation when assessing sputum samples.

Following randomisation of eligible patients, patients will be asked to return to the hospital for a second visit (within 1 week) to collect their medication from the research fellow who will instruct the patient to start taking the medication within 3 days. At this visit, the research team will check if patients are happy filling in their diary cards and will be happy to answer any questions they may have.

In week 5 and week 9 of treatment, each patient will be contacted by telephone to:

• Monitor progress and compliance.
• Remind patients to take medication.
• Encourage patients to contact the GP/investigator if symptoms worsen.
• The occurrence of any adverse effects/serious adverse effects (AE/SAE) or an exacerbation will be checked and recorded.
• Remind patients to fill in their daily diary cards

End of Study Visit (at week 14):

Patients will be asked to return to the hospital and the following assessments will be made:

• The occurrence of AE/SAE or exacerbations will be checked and recorded.
• A spirometry assessment to test their lung function.
• Diary cards will be collected by the investigator.
• SGRQ and EQ5D questionnaires will be completed at this visit by the patient.
• A sputum sample will be taken from the patients to determine bacterial number in their lung.
• Unused study medication and packaging will be collected from the patient.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 200 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Participant)
• Official Title: A Phase III Single-blind, Randomised Placebo Controlled Trial of Long Term Therapy in Patients With Stable COPD Using Moxifloxacin, Azithromycin and Doxycycline: a Bayesian Decision Analysis, Including Other Criteria, Will be Used to Distinguish the Optimal Antibiotic Treatment
• Study Start Date: December 2011
• Estimated Primary Completion Date: January 2013
• Estimated Study Completion Date: April 2013

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Moxifloxacin	Drug: Moxifloxacin; An oral dose of 400 mg once daily for 5 consecutive days every 4 weeks.
Active Comparator: Azithromycin	Drug: Azithromycin; An oral dose of 250 mg once daily three times a week (every other day).
Active Comparator: Doxycycline	Drug: Doxycycline; An oral dose of 100 mg once daily.
Placebo Comparator: Placebo	Drug: Placebo; Oral dose of one table once daily.

Outcome Measures

Primary Outcome Measures :

1. To measure and compare reduction in the concentration of lower airway bacteria in patients with COPD between three different antibiotic regimes and placebo [ Time Frame: Week 14 post treatment ]

Secondary Outcome Measures :

1. To measure changes in lung function measure, health status and exacerbations. [ Time Frame: week 14 post treatment ]

Eligibility Criteria

• Ages Eligible for Study: 45 Years to 80 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Confirmed COPD diagnosis
• Informed Consent: Patients must give their signed and dated written informed consent to participate
• Gender: Male or female patients
• Age: ≥ 45 years of age at screening
• Produce sputum regularly (produce sputum in at least 3 months of a year)
• Able to complete questionnaires for health status and symptoms and considered able to comply with the dosing regimen.
• Severity of disease: Patients with a measured FEV1<80% of predicted normal values as determined at screening. An average of three spirometry readings will be taken.

Exclusion Criteria:

• Patients with TB, other chronic respiratory disease (e.g. chronic asthma, bronchiectasis, pulmonary fibrosis), patients with hepatic or renal impairment and patients with prolonged QT interval and other cardiac abnormalities.
• Patients with known hypersensitivity to the antibiotics under evaluation.
• Patients on long term antibiotics for other conditions.
• Patients with uncontrolled hypertension.
• Female patients who are pregnant or planning on becoming pregnant during the study, or are breastfeeding.
• Patients with a history of long QT syndrome or whose QTc measured at Visit 1 is prolonged (>450 msec for males and females) as confirmed by the ECG assessor.
• Clinically relevant abnormal laboratory values at the screening assessment that could interfere with the objectives of the trial or safety of the volunteer.
• Patient taking clinically significant contraindicated medication, as per the SmPCs

Contacts and Locations

Contacts

Contact: Ethaar El-Emir, PhD; 0044 2073177510; ethaar.el-emir@nhs.net

Locations

United Kingdom

Academic Unit of Respiratory Medicine, Royal Free Hospital; Recruiting

London, United Kingdom, NW3 2PF

Contact: Ethaar El-Emir, PhD 0044 2073177510 ethaar.el-emir@nhs.net

Principal Investigator: Jadwiga A Wedzicha, MA, MD, FRCP

Sponsors and Collaborators

University College, London

Royal Free Hampstead NHS Trust

University of Cambridge

National Institute for Health Research, United Kingdom

Investigators

• Principal Investigator: Jadwiga A Wedzicha; University College, London

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Brill SE, Law M, El-Emir E, Allinson JP, James P, Maddox V, Donaldson GC, McHugh TD, Cookson WO, Moffatt MF, Nazareth I, Hurst JR, Calverley PM, Sweeting MJ, Wedzicha JA. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax. 2015 Oct;70(10):930-8. doi: 10.1136/thoraxjnl-2015-207194. Epub 2015 Jul 15.

• Responsible Party: Alison Evans, University College London
• ClinicalTrials.gov Identifier: NCT01398072
• Other Study ID Numbers: 11/0078
• First Posted: July 20, 2011
• Last Update Posted: June 1, 2012
• Last Verified: May 2012

Additional relevant MeSH terms:

Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Azithromycin; Moxifloxacin; Doxycycline; Anti-Bacterial Agents; Anti-Infective Agents; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Antimalarials; Antiprotozoal Agents; Antiparasitic Agents